Table V.

Individual SNPs associated with survival in NSCLC patients treated with curative therapy (q < 0.1)

SNP	Gene	Chr	SNP location	Allelic change	MAF	Overall
						Best model	HR (95% CI)a	P value	q value
rs4135385	CTNNB1	3	Intron	A>G	0.25	Recessive	3.74 (2.23–6.29)	6.02×10−7	1.43× 10−4
rs10898563	FZD4	11	3′ UTR	A>G	0.35	Recessive	2.29 (1.60–3.28)	5.19×10−6	3.46×10−4
rs503022	WNT5A	3	3′ flanking	C>A	0.16	Recessive	4.34 (2.30–8.18)	5.82×10−6	3.46×10−4
rs629537b	WNT5A	3	3′ flanking	G>A	0.16	Recessive	4.34 (2.30–8.18)	5.82×10−6	3.46×10−4
rs11658976	WNT3	17	Intron	A>G	0.40	Recessive	1.89 (1.31–2.73)	6.43×10−4	0.0306
rs3765351	WNT4	1	3′ UTR	A>G	0.44	Recessive	1.82 (1.28–2.59)	9.24×10−4	0.0366
rs713065	FZD4	11	3′ UTR	A>G	0.37	Dominant	0.63 (0.47–0.85)	0.0022	0.0752

Underlined bold numbers denote significant association at q < 0.1. MAF, minor allele frequency; UTR, untranslated region.

^aAdjusted for sex, age, race, clinical stage, pack year tobacco history and treatment regimen.

^bShowed linkage with rs503022, r ² = 0.99.